RA
Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
$39.66 -0.94% (-$0.38)
1M -19.60%
Market Cap $2.01B
P/E Ratio -
Div. Yield -
ROE 29.02%
Piotroski F-Score Weak
2/9Valuation
21 /100
Expensive P/B 4.74x
P/S 100.32x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 191.81%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 685.80%
Op. margin 767.58%
FCF margin 485.75%
Quality
1 /100
Poor ROE 29.02%
ROA 29.88%
Asset turnover 0.04x
Debt
100 /100
Low Current ratio 15.72x
Debt/Equity 0.02x
Net debt/EBITDA N/A
Stability
31 /100
Unstable EPS volatility 169.43%
Profitable years 0
Beta 1.03x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o RAPP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Abraham N. Ceesay
Employees
84
Headquarters
Boston
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report